High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Transforming mutations in NRAS and KRAS are thought to play a causative role in the development of numerous cancers, including myeloid malignancies. Although mutations at amino acids 12, 13, or 61 account for the majority of oncogenic Ras variants, we hypothesized that less frequent mutations at alternate residues may account for disease in some patients with cancer of unexplained genetic etiology. To search for additional, novel RAS mutations, we sequenced all coding exons in NRAS, KRAS, and HRAS in 329 acute myeloid leukemia (AML) patients, 32 chronic myelomonocytic leukemia (CMML) patients, and 96 healthy individuals. We detected 4 “noncanonical” point mutations in 7 patients: N-RasG60E, K-RasV14I, K-RasT74P, and K-RasA146T. All 4 Ras mutants exhibited oncogenic properties in comparison with wild-type Ras in biochemical and functional assays. The presence of transforming RAS mutations outside of positions 12, 13, and 61 reveals that alternate mechanisms of transformation by RAS may be overlooked in screens designed to detect only the most common RAS mutations. Our results suggest that RAS mutations may play a greater role in leukemogenesis than currently believed and indicate that high-throughput screening for mutant RAS alleles in cancer should include analysis of the entire RAS coding region.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
Cited by
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
“A new perspective on the issue of the contributions of particular amino acid substitutions to the in vivo transforming capabilities of RAS has been added by recent findings that have documented previously uncharacterized RAS mutations in colorectal tumours and leukaemia”
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3314 · Cited by 545
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias
for The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project, Andersson, A. K., Ma, J., Wang, J., Chen, X., Gedman, A. L., Dang, J., Nakitandwe, J., Holmfeldt, L., Parker, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3230 · Cited by 490
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
Vaughn, C. P., ZoBell, S. D., Furtado, L. V., Baker, C. L., & Samowitz, W. S. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20854 · Cited by 377
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
Metadata
- Authors
- Tyner, J. W., Erickson, H., Deininger, M. W. N., Willis, S. G., Eide, C. A., Levine, R. L., Heinrich, M. C., Gattermann, N., Gilliland, D. G., Druker, B. J., & Loriaux, M. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-02-19
- Volume
- 113
- Issue
- 8
- Pages
- 1749-1755
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1981125188
- Cited by
- 131
- References
- 2
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. https://app.cochat.ai/papers/10.1182/blood-2008-04-152157
- The paper
- Tyner, J. W., Erickson, H., Deininger, M. W. N., Willis, S. G., Eide, C. A., Levine, R. L., Heinrich, M. C., Gattermann, N., Gilliland, D. G., Druker, B. J., & Loriaux, M. M. (2009). High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. https://doi.org/10.1182/blood-2008-04-152157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.